Australia's most trusted
source of pharma news
Saturday, 15 March 2025
Posted 13 March 2025 AM
The fight over patents covering Bayer's anticoagulant Xarelto has heard the final bell, with the High Court of Australia refusing to hear Bayer's appeal over an invalidity finding made by the Full Court last October.
Last year, in a case brought by Sandoz, the Full Court concluded that two of Bayer's patents covering Xarelto were invalid for lack of an inventive step, and ordered Bayer to pay most of Sandoz's costs.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.